Physician profile
Pei Lu
NPI 1396129169
$1,644.40
in general payments reported to CMS, 2019-2025
19 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $285 · 2021: $249 · 2023: $191 · 2024: $331 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.00 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $304.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $238.23 | 2020-2024 | Tagrisso |
| Incyte Corporation | $198.95 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $142.53 | 2025 | Onivyde |
| Pfizer INC. | $100.56 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.80 | 2019 | |
| Daiichi Sankyo INC. | $98.99 | 2024 | Enhertu |
| Merck Sharp & Dohme LLC | $65.20 | 2024-2025 | Keytruda, Welireg |
| Conmed Corporation | $59.56 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $49.73 | 2021 | |
| Genzyme Corporation | $44.19 | 2023 | |
| Glaxosmithkline, LLC. | $29.78 | 2024 | Zejula |
| Karyopharm Therapeutics INC. | $28.84 | 2024 | Xpovio |
| Novartis Pharmaceuticals Corporation | $24.88 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.43 | 2024 | Padcev |
| Acrotech Biopharma INC. | $18.64 | 2023 | Beleodaq |
| Lilly USA, LLC | $17.34 | 2025 | Verzenio |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pei Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.